716 results on '"Lenting, Peter J."'
Search Results
2. Fitusiran reduces bleeding in factor X–deficient mice
3. Plasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosis
4. Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor
5. Type 2N von Willebrand disease: genotype drives different bleeding phenotypes and treatment needs
6. How unique structural adaptations support and coordinate the complex function of von Willebrand factor
7. Angiopoietin-2 binds to multiple interactive sites within von Willebrand factor
8. Transplacental delivery of therapeutic proteins by engineered immunoglobulin G: a step toward perinatal replacement therapy
9. Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in von Willebrand disease murine models
10. Antithrombin lowering in hemophilia: a closer look at fitusiran
11. A reactive center loop–based prediction platform to enhance the design of therapeutic SERPINs
12. A nanobody against the VWF A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired VWD
13. Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab
14. Mortality, cardiac and cerebral damages reduction by IL-1 inhibition in a murine model of TTP
15. Antithrombotic potential of a single‐domain antibody enhancing the activated protein C‐cofactor activity of protein S
16. Osteoprotegerin modulates platelet adhesion to von Willebrand factor during release from endothelial cells
17. Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis
18. Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID‐19
19. Camelid‐derived single‐chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications
20. The Role of Platelets and von Willebrand Factor in the Procoagulant Phenotype of Inflammatory Bowel Disease.
21. Development and characterization of single‐domain antibodies neutralizing protease nexin‐1 as tools to increase thrombin generation
22. Laboratory monitoring of hemophilia A treatments: new challenges
23. Differences in venous clot structures between hemophilic mice treated with emicizumab versus factor VIII or factor VIIIFc
24. The role of platelets and von Willebrand factor in the procoagulant phenotype of inflammatory bowel disease
25. Shear Forces Induced Platelet Clearance Is a New Mechanism of Thrombocytopenia
26. A single‐domain antibody that blocks factor VIIa activity in the absence but not presence of tissue factor
27. Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia
28. von Willebrand Factor and Management of Heart Valve Disease: JACC Review Topic of the Week
29. Structure and dynamics of the platelet integrin-binding C4 domain of von Willebrand factor
30. IdeS, a new option to optimize the management of patients with hemophilia A on emicizumab
31. Real-Time Monitoring of von Willebrand Factor in the Catheterization Laboratory: The Seatbelt of Mini-Invasive Transcatheter Aortic Valve Replacement?
32. Arterial Pulsatility and Circulating von Willebrand Factor in Patients on Mechanical Circulatory Support
33. Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins
34. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
35. Endotheliopathy Is Induced by Plasma From Critically Ill Patients and Associated With Organ Failure in Severe COVID-19
36. Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions
37. Author Correction: Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins
38. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A
39. VON WILLEBRAND FACTOR: FROM FIGURANT TO MAIN CHARACTER IN THE SCENE OF INFLAMMATION
40. Macrophage receptor SR-AI is crucial to maintain normal plasma levels of coagulation factor X
41. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends
42. A nanobody against the von Willebrand factor A3-domain detects ADAMTS13-induced proteolysis in congenital & acquired VWD
43. A FVIII-Mimetic Bispecific Antibody with an Embedded Self-Regulation Mechanism Reduces the Risk of Prothrombotic Events for the Treatment of Haemophilia a
44. P.31 Von Willebrand Factor Induces Vascular Smooth Muscle Cell Proliferation and Migration Through Low Density Lipoprotein-Related Receptor Protein 4 and αvβ3 Integrin
45. Cerebral Microbleeds During Transcatheter Aortic Valve Replacement: A Prospective Magnetic Resonance Imaging Cohort
46. von Willebrand Factor for Aortic Valve Intervention: From Bench to Real-Time Bedside Assessment
47. Abstract 19793: Pulsatility Modulates the Acquired Von Willebrand Factor Defect Related to Mechanical Circulatory Support Devices
48. Transient von Willebrand factor‐mediated platelet influx stimulates liver regeneration after partial hepatectomy in mice
49. Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B–associated thrombocytopenia
50. Towards novel treatment options in von Willebrand disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.